[Do other proton pump blockers have advantages over Antra (omeprazole)?].
Creutzfeldt
W
W
Medizinische Universitätsklinik, Göttingen.
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077402:Pantoprazole; D010437:Peptic Ulcer / Q000097:blood / Q000188:drug therapy*; D013329:Structure-Activity Relationship; D013454:Sulfoxides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D013454:Sulfoxides; D064747:Lansoprazole; D000077402:Pantoprazole; D009853:Omeprazole
Bringen andere Protonenpumpenblocker gegenüber Antra (Omeprazol) Vorteile?